EGFR and non-small cell lung carcinoma: PPS will exert higher impact on the OS of patients with NSCLC harboring EGFR T790M mutations treated with first or second‐generation EGFR‐TKIs as the first‐line treatment when osimertinib is used as the second‐line treatment.